Testing for Slideshow

/   /   /   /   Save Image  

asas

1564004076617_5d3888ac06299c0004d4254f_logo

Global Arena Holding Inc.

558c6a265e4e180009f5227e_logo

martial_arts

54dd0edd7f9d3d0009af474c_logo

1555102157573_5c7ea78883c747000486abc8_logo

Veritas Farms CEO Provides Update to Shareholders on Recent Corporate and Business Developments

Fort Lauderdale, FL - (NewMediaWire) - October 14, 2019 - Veritas Farms, Inc. (OTCQB:VFRMD) (“Veritas Farms” or the “Company”), a vertically integrated agribusiness focused on the production of full spectrum hemp oil products with naturally occurring cannabinoids, is pleased to share CEO and Co-Founder Alexander Salgado’s letter to shareholders discussing recent corporate and business developments.  The letter reads as follows:Dear Fellow Shareholders,I would like to take this opportunity to explain the rationale behind our recent decision to enact a reverse stock split. This step was not taken lightly and was necessary to reduce the number of outstanding shares and otherwise properly capitalize our Company in order to position us to uplist our stock from the OTCQB to a national securities exchange. In addition, in connection therewith, we have enhanced our corporate governance by expanding our board of directors so that a majority of the board consists of independent directors and by establishing audit, compensation and nominating and corporate governance committees, the members of which are our independent directors.  We believe that positioning Veritas Farms for an uplisting of its common stock to a national securities exchange, will be a significant step forward and the culmination of four years of hard effort, all made possible by the support of you, our shareholders.2019 has proven to be a period of significant growth for the Company.We have reported a 500% increase in year to year revenue for the 6 months ended June 30, 2019, from $818,585 in 2018 to $4,496,275 in 2019, and we expect to see continued growth over the balance of this year.  This sustained revenue growth has been made possible thanks to an aggressive expansion of our retailer and distributor network. We now count more than 4,500 retailers and distributors as partners within our rapidly expanding network. We expect this trend to continue and for Veritas Farms™ brand products to be stocked on shelves and warehouses around the country and internationally.We have also successfully completed two private placement financings over the past 24 months. This has provided us with an infusion of capital in excess of $20 million. This capital is being deployed to fuel our continued efforts to expand our retailer and distribution network, implement additional sales and marketing platforms, expand our infrastructure, fill key management and administrative positions, and develop several exciting new category and product launches over the remainder of 2019 and beyond.An excellent example of this capital being put to good use is the growth of our 100% owned and operated 140-acre farm and production facility in Pueblo, Colorado. Key enhancements have been made to our farming infrastructure and processes which have increased our 2019 yields by as much as five times compared to our 2018. This will allow us to meet the rapidly rising demand for Veritas Farms™ full spectrum hemp products.We believe the completion of the reverse stock split, enhancements to the Company’s corporate governance, our achievements in expanding Veritas Farms’ business and revenues, and our raising of significant capital to fund operations are all necessary steps in positioning Veritas Farms to uplist its common stock to a national securities exchange.I look forward to sharing more developments with you in the near future.Sincerely,Alexander M. SalgadoCEO and co-FounderAbout Veritas Farms, Inc.Veritas Farms, Inc. (OTCQB:VFRM) is a vertically integrated agribusiness focused on producing superior quality, whole plant, full spectrum hemp oils and extracts containing naturally occurring cannabinoids.  The Company currently owns and operates a 140-acre farm and production facilities in Pueblo, Colorado, and is registered with the Colorado Department of Agriculture to grow industrial hemp.  The Company markets and sells products under its Veritas Farms™ brand and manufactures private label products for a number of leading distributors and retailers.  Veritas Farms™ brand full spectrum hemp oil ...

Qrons Granted Exclusive World-Wide License by Dartmouth College for Intellectual Property Related to 3D Printable Materials in Human and Animal Health

Qrons is Developing 3D Printable Implants to Treat Penetrating Brain InjuriesNEW YORK, NY - (NewMediaWire) - October 14, 2019 - Qrons Inc. (OTCQB: QRON), an emerging biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions for the treatment of traumatic brain injuries, including concussions and penetrating injuries, announced today that it has entered into an Intellectual Property License Agreement (the “Agreement”) with Dartmouth College for an exclusive world-wide license of Intellectual Property related to 3D printable materials in the fields of human and animal health. The Agreement provides for the payment by Qrons of initial and annual license fees and royalty payments based upon Qrons' product sales. The Agreement was signed on October 2, 2019 and is effective as of September 3, 2019. Qrons is using the 3D process covered by the patent entitled “Mechanically Interlocked Molecules-based Materials for 3D Printing” as part of its injury specific 3D printable implants to treat penetrating brain injuries. Qrons is also a party to a Sponsored Research Agreement with Dartmouth to advance the license or ownership of additional Intellectual Property. The Qrons research team is working closely with Professor Chenfeng Ke, a member of Qrons Scientific Advisory Board and an inventor of the licensed 3D process, and PhD candidate Qianming Lin. Ido Merfeld, Qrons Co-founder and Head of Product, commented, “The intellectual property covered by this license has been instrumental in helping us advance our research on the treatment of penetrating brain injuries. We believe combining Qrons’ proprietary hydrogel with customizable 3D printing capabilities is an innovative approach to treating traumatic brain injuries, for which there are limited treatments.”Jonah Meer, Qrons’ Co-founder and CEO, added, “We’re excited to have concluded negotiations to acquire an exclusive license for this important intellectual property. There is a great need for our promising treatments, and this technology is an integral part of our work to develop innovative 3D printable, biocompatible advanced materials.”Chenfeng Ke, Assistant Professor of Chemistry, Dartmouth College, stated, “We are excited to partner with Qrons and continue the development of smart hydrogels with 3D printing capability for the treatment of traumatic brain injuries.”Nila Bhakumi, Director of Technology Transfer at Dartmouth, echoed Professor Ke’s comments and added, “We are delighted with Dr. Ke’s collaboration with Qrons as they try to solve the very important problem of Traumatic Brain Injury.”About Dartmouth CollegeFounded in 1769, Dartmouth College is a member of the Ivy League and consistently ranks among the world's greatest academic institutions. Dartmouth has forged a singular identity for combining its deep commitment to outstanding undergraduate liberal arts and graduate education with distinguished research and scholarship in the Arts & Sciences and its three leading professional schools - the Geisel School of Medicine, Thayer School of Engineering, and the Tuck School of Business.About Qrons Inc. Headquartered in New York City, Qrons is a publicly traded emerging biotechnology company developing advanced stem cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries and concussions. The Company has two product candidates for treating TBIs, both integrating proprietary, modified mesenchymal stem cells ("MSCs") and smart synthetic material, QS100™, an injury specific, 3D printable, implantable MSCs-synthetic hydrogel, to treat penetrating brain injuries and QS200™, an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries commonly referred to as concussions.  The Company is a party to a license and research funding agreement and related service agreements with Ariel Scientific Innovations Ltd., a wholly owned subsidiary of Ariel University, based in Ariel, Israel, and in addition to the world-wide exclusive intellectual property license, a Sponsored Research Agreement with Dartmouth ...